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Abstract We previously conducted nationwide surveil-
lance of Streptococcus pneumoniae in 2000–2001 (period 1)
and 2004 (period 2) and reported the ﬁndings. Subsequent
surveillance surveys conducted in 2007 (period 3) and 2010
(period 4) are now reported. Bacterial strains were clinically
isolated from children with meningitis, sepsis, and respira-
tory tract infections at 27 hospitals participating in the Drug-
Resistant Pathogen Surveillance Group in Pediatric Infec-
tious Disease. Twenty-one drugs were investigated for 283
isolated strains in period 3, and 24 drugs were investigated
for 459 strains in period 4. In period 3, 43.8 % of strains were
penicillin-susceptible S. pneumoniae (PSSP), 52.3 % were
penicillin-intermediate S. pneumoniae (PISP), and 3.9 %
were penicillin-resistant S. pneumoniae (PRSP). In period 4,
the percentages were PSSP 23.1 %, PISP 49.9 %, and PRSP
27.0 %. The resistance rates were 56.2 % and 76.9 %,
respectively. Drug sensitivity was best with panipenem, at a
minimum inhibitory concentration (MIC)90B0.063 lg/ml in
period 3, and with tebipenem (MIC90 B 0.063 lg/ml) in
period 4. Patients’ background factors related to increased
bacterial resistance were investigated, and signiﬁcant dif-
ferences were found depending on whether a child had sib-
lings (P = 0.0056) or was a daycare center attendee
(P = 0.0195) in period 3, and age category (P = 0.0256) in
period 4. No factors were common to both periods 3 and 4.
Pneumococcus is a major causative organism of pediatric
infectious disease, and we plan to continue conducting sur-
veillance and providing information in the future.
Keywords Drug resistance  Pediatric infectious disease 
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Introduction
Together with Haemophilus inﬂuenzae and Moraxella
catarrhalis, Streptococcus pneumoniae is a main causative
organism of otorhinolaryngological infections and respira-
tory tract infections in children. S. pneumoniae in particular
is a major causative organism for sepsis and purulent men-
ingitis after infancy, and it is considered to be one of the most
important bacterial strains causing infections [1, 2].
In recent years, the increase in penicillin-intermediate
S. pneumoniae (PISP) and penicillin-resistant S. pneumoniae
(PRSP), which show resistance to penicillins, is becoming
a problem. It has also been reported that sensitivity to
cephems and carbapenems is decreasing, which is a factor
in making respiratory tract and otorhinolaryngological
infections in children more intractable and their treatment
more difﬁcult [3].
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Amid the trend of increasing resistance of S. pneumo-
niae, our group has surveyed drug sensitivity over time
since 2000. The results of nationwide surveys conducted in
2007 (period 3) and 2010 (period 4), following earlier
surveys in 2000–2001 (period 1) and 2004 (period 2) [4],
are now reported.
Materials and methods
Subjects
Among the strains clinically isolated from children with
meningitis, sepsis, and respiratory infection at 27 facilities
that participated in the nationwide Drug-Resistant Patho-
gen Surveillance Group in Pediatric Infectious Disease
between January and June 2007 (period 3) and January and
June 2010 (period 4), 283 strains and 459 strains were
investigated in each period, respectively, that were judged
by the physicians in charge to be causative organisms
based on the amount of bacteria, laboratory test, and
patients’ clinical symptoms.
The number of strains isolated from various specimens
was calculated in each period, and the following results
were obtained: blood (7 strains), swabs collected from the
nasopharynx (251 strains), sputum (21 strains), ear dis-
charge (1 strain), and unknown (3 strains) in period 3, and
blood (23 strains), spinal ﬂuid (1 strain), swabs collected
from the nasopharynx (392 strains), sputum (41 strains),
and unknown (2 strains) in period 4.
In addition, to determine the origin of each strain, fac-
tors such as sex, age, presence or absence of siblings,
presence or absence of group childcare, presence or
absence of previous treatment with antibacterial agents,
and the location of the hospital were investigated. The
present study was reviewed and approved by the ethics
committee of each facility in accordance with their
regulations.
Measured drugs
In testing sensitivity, 21 drugs were used in period 3
[penicillin G (PCG), ampicillin (ABPC), amoxicillin
(AMPC), cefaclor (CCL), cefditoren (CDTR), cefcapene
(CFPN), cefpodoxime (CPDX), cefdinir (CFDN), cefotiam
(CTM), ceftriaxone (CTRX), cefotaxime (CTX), cefteram
(CFTM), azithromycin (AZM), clarithromycin (CAM),
rokitamycin (RKM), faropenem (FRPM), panipenem
(PAPM), meropenem (MEPM), vancomycin (VCM), teli-
thromycin (TEL), and levoﬂoxacin (LVFX)]; and 24 drugs
were used in period 4 [PCG, ABPC, AMPC, piperacillin
(PIPC), CCL, CDTR, CFPN, CPDX, CFDN, CTM, CTRX,
CTX, CFTM, AZM, CAM, RKM, FRPM, PAPM, MEPM,
doripenem (DRPM), tebipenem (TBPM), VCM, LVFX,
and tosuﬂoxacin (TFLX)].
Sensitivity testing and analysis
Isolation, culturing, and identiﬁcation were conducted at
each facility, and all sensitivity measurements were con-
ducted at Kitasato University. To test sensitivity, the
minimum inhibitory concentration (MIC) was measured
using the broth microdilution method [5] according to
Clinical and Laboratory Standards Institute (CLSI) meth-
ods. Then, in accordance with the CLSI standards for oral
antibacterial agents (nonmeningitis1, oral penicillin), PCG
sensitivity of B0.06 lg/ml was classiﬁed as PSSP, sensi-
tivity of 0.12–1.0 lg/ml was classiﬁed as PISP, and sen-
sitivity of C2.0 lg/ml was classiﬁed as PRSP [6].
In addition, strains from sterile sites accounted for less
than 10 % of the overall strains, speciﬁcally 7 strains
(blood) in period 3 and 24 strains in period 4 (cerebrospinal
ﬂuid, n = 1; blood, n = 23), and therefore no investigation
by origin was conducted for them.
An analysis by patient background was also done to
identify factors related to increased resistance. The analysis
was done using the v2 test with a two-sided signiﬁcance
level of 0.05. In cases when the expected value was B10,
Fisher’s exact probability test was used.
Results
Drug sensitivity
The drug sensitivity results are shown in Table 1 for period
3 (2007) and in Table 2 for period 4 (2010).
In period 3, 124 (43.8 %) strains were PSSP, 148
(52.3 %) strains were PISP, and 11 (3.9 %) strains were
PRSP. PISP ? PRSP accounted for 56.2 %. The best MIC90
of the antibacterial agents tested was for PAPM (B0.063 lg/
ml), followed by CDTR, FRPM, MEPM VCM, and TEL
(0.25 lg/ml). By type of sensitivity, the MIC90 values of
PCG, ABPC, AMPC, FRPM, PAPM, and MEPM were the
most active for PSSP, at B0.063 lg/ml. PAPM had an
MIC90 value of 0.125 lg/ml for PISP, and PAPM and VCM
had MIC90 values of 0.25 lg/ml for PRSP.
In period 4, 106 (23.1 %) strains were PSSP, 229
(49.9 %) strains were PISP, and 124 (27.0 %) strains were
PRSP. PISP ? PRSP accounted for 76.9 %. The best
MIC90 of the antibacterial agents tested was for TBPM
(B0.063 lg/ml), followed by PAPM (0.125 lg/ml). With
respect to the MIC90 for PSSP, the best antibacterial agents
were PCG, AMPC, PIPC, FRPM, TBPM, PAPM, MEPM,
and DRPM, at B0.063 lg/ml. TBPM had the best MIC90
values for PISP and PRSP, at B0.063 lg/ml.
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Resistance rates for each background factor
The resistance rates for background factors for the strains
and the resistance rate with each background factor in
periods 3 and 4 are shown in Tables 3 and 4, respectively.
Looking at the background factors for 283 strains in
period 3, C70 % of strains were from toddlers and pre-
schoolers (71.7 %, 203 strains). Other background factors
were being male (52.3 %, 148 strains), having siblings
(54.1 %, 153 strains), daycare center attendee (54.8 %, 155
strains), and having previously received antibacterial agents
(55.1 %, 156 strains). No signiﬁcant differences were seen.
Of the background factors for 459 strains in period 4, the
most were related to being male (59.3 %, 272 strains),
being a toddler or preschooler (71.9 %, 330 strains), and
having siblings (59.7 %, 274 strains). Other background
factors were daycare center attendee (54.7 %, 251 strains)
and having previously received antibacterial agents
(55.6 %, 255 strains). However, no signiﬁcant differences
were seen.
In period 3, drug-resistant strains were related to day-
care center attendance (P = 0.0195). In period 4, there
were signiﬁcantly more such strains by age category
(P = 0.0256).
Discussion
Because penicillins have shown superior antibacterial
activity against S. pneumoniae, refractory cases of pediatric
respiratory tract infections have been rare. In recent years,
however, PRSP that show resistance to penicillins, cep-
hems, and carbapenems are increasing rapidly. The number
of cases in which there is difﬁculty in treating acute otitis
media or respiratory tract infections is growing, and the
increasing drug resistance of S. pneumoniae is becoming a
serious problem. [4].
Surveillance of S. pneumoniae strains derived from
pediatric infections was conducted to conﬁrm the state of
drug resistance increases in S. pneumoniae from October
Table 1 Drug susceptibility in period 3 (2007)
Drug MIC range (lg/ml) S. pneumoniae PSSP PISP PRSP
MIC50
(lg/ml)
MIC90
(lg/ml)
MIC50
(lg/ml)
MIC90
(lg/ml)
MIC50
(lg/ml)
MIC90
(lg/ml)
MIC50
(lg/ml)
MIC90
(lg/ml)
PCG B0.063–2 0.25 1 B0.063 B0.063 0.5 1 2 2
ABPC B0.063–8 0.25 2 B0.063 B0.063 1 2 4 4
AMPC B0.063–4 0.25 1 B0.063 B0.063 0.5 1 1 4
CCL 0.125–128 4 64 0.5 4 16 64 128 128
CDTR B0.063–4 0.125 0.25 B0.063 0.25 0.25 0.5 0.5 0.5
CFPN B0.063–8 0.25 0.5 0.125 0.5 0.5 1 1 1
CPDX B0.063–64 1 2 0.25 1 1 2 2 4
CFDN B0.063–16 1 4 0.25 1 2 4 4 8
CTM B0.063–8 1 4 0.25 1 2 4 4 8
CTRX B0.063–8 0.25 1 0.125 0.5 0.5 1 1 1
CTX B0.063–8 0.5 0.5 0.125 0.5 0.5 1 1 1
CFTM B0.063–8 0.25 1 0.125 0.5 0.5 1 1 1
AZM B0.063–64 [64 [64 [64 [64 [64 [64 [64 [64
CAM B0.063 to[64 [64 [64 64 [64 [64 [64 [64 [64
RKM B0.063 to[32 1 [32 2 [32 1 [32 [32 [32
FRPM B0.063–1 B0.063 0.25 B0.063 B0.063 0.25 0.25 0.5 0.5
PAPM B0.063–0.5 B0.063 B0.063 B0.063 B0.063 B0.063 0.125 B0.063 0.25
MEPM B0.063–0.5 B0.063 0.25 B0.063 B0.063 0.125 0.25 0.5 0.5
VCM 0.125–0.5 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25
TEL B0.063–1 B0.063 0.25 B0.063 0.25 B0.063 0.25 0.125 0.5
LVFX 0.5–2 1 1 1 2 1 1 1 2
ABPC ampicillin, AMPC amoxicillin, AZM azithromycin, CAM clarithromycin, CCL cefaclor, CDTR cefditoren, CFDN cefdinir, CFTM ce-
fteram, CPDX cefpodoxime, CTM cefotiam, CTRX ceftriaxone, CTX cefotaxime, FRPM faropenem, LVFX levoﬂoxacin, MEPM meropenem,
PAPM panipenem, PCG penicillin G, PISP penicillin-intermediate S. pneumoniae, PRSP penicillin-resistant S. pneumoniae, PSSP penicillin-
susceptible S. pneumoniae, RKM rokitamycin, TEL telithromycin, VCM vancomycin
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2000 to July 2001 (period 1) and from January to June
2004 (period 2), and the ﬁndings were reported. Sub-
sequent surveillance surveys were then conducted in period
3 and period 4.
The resistance rates were 56.2 % in period 3 and 76.9 %
in period 4, more than half in both periods and showing an
increasing trend. A rapid increase was seen in PRSP in
particular, from 3.9 to 27.0 %. Investigation of the resis-
tance rate by background factor revealed no common fac-
tors that showed signiﬁcant differences in both period 3
and period 4, despite the signiﬁcant differences seen with
age category in periods 4 and 3, respectively. At the current
time, no individual factor responsible for the increases in
bacterial resistance can be identiﬁed.
However, PISP ? PRSP accounted for 64.6 % in period
1, 66.9 % in period 2, 56.2 % in period 3, and 76.9 % in
period 4, with a decrease in period 3. Looking at PRSP
only, the proportions were 29.8, 29.8, 3.9, and 27.0 %,
respectively, decreasing markedly in period 3.
Jaecklin et al. conducted a survey on patients under
16 years old in Switzerland [7] and reported the isolation
frequency of PISP ? PRSP between 1989 and 2004. The
isolation frequency, which was 2 % in 1989, maintained a
20 % level during the period after 1994 and reached 41 %
in 2004. The trend observed in this survey was similar to
that observed in the Japanese survey, although these sur-
veys were conducted during different periods. Because
pneumococci are becoming increasingly resistant to drugs
around the world, close surveillance should be conducted
continuously.
In a nationwide survey conducted by Suzuki et al. [8] in
the ﬁeld of otorhinolaryngology, the isolation frequencies
in 1994, 1998, 2003, and 2008 were 36.1, 29.1, 39.7, and
33.3 %, respectively, for PISP, 14.3, 21.8, 19.9, and
Table 2 Drug susceptibility in period 4 (2010)
Drug MIC range
(lg/ml)
S. pneumoniae PSSP PISP PRSP
MIC50
(lg/ml)
MIC90
(lg/ml)
MIC50
(lg/ml)
MIC90
(lg/ml)
MIC50
(lg/ml)
MIC90
(lg/ml)
MIC50
(lg/ml)
MIC90
(lg/ml)
PCG B0.063–4 1 2 B0.063 B0.063 0.5 1 2 2
ABPC B0.063–8 0.5 2 B0.063 0.125 0.5 2 2 4
AMPC B0.063–4 0.25 1 B0.063 B0.063 0.25 1 1 2
PIPC B0.063–4 0.5 2 B0.063 B0.063 0.5 2 2 2
CCL B0.063–128 16 64 1 2 16 32 64 128
CDTR B0.063–8 0.25 1 0.125 0.5 0.25 0.5 0.5 1
CFPN B0.063–16 0.5 1 0.25 0.5 0.5 1 1 2
CPDX B0.063–16 1 2 0.5 2 1 2 2 4
CFDN B0.063–32 2 8 0.25 1 2 4 4 8
CTM B0.063–16 1 8 0.25 0.5 1 4 4 8
CTRX B0.063–8 0.5 1 0.25 0.5 0.5 1 1 2
CTX B0.063–16 0.5 1 0.25 0.5 0.5 1 1 2
CFTM B0.063–16 0.5 1 0.25 1 0.5 1 1 2
AZM B0.063 to[64 [64 [64 [64 [64 [64 [64 [64 [64
CAM B0.063 to[64 [64 [64 [64 [64 [64 [64 [64 [64
RKM B0.063–[32 2 [32 8 [32 2 [32 2 [32
FRPM B0.063–1 0.125 0.5 B0.063 B0.063 0.125 0.25 0.25 0.5
PAPM B0.063–0.5 B0.063 0.125 B0.063 B0.063 B0.063 0.125 B0.063 0.25
MEPM B0.063–1 0.125 0.5 B0.063 B0.063 0.125 0.25 0.25 0.5
DRPM B0.063–1 B0.063 0.5 B0.063 B0.063 B0.063 0.25 0.25 0.5
TBPM B0.063–0.125 B0.063 B0.063 B0.063 B0.063 B0.063 B0.063 B0.063 B0.063
VCM B0.063–0.5 0.25 0.5 0.25 0.5 0.25 0.5 0.25 0.5
LVFX 0.5–2 1 2 1 2 1 2 1 2
TFLX B0.063–0.5 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25
ABPC ampicillin, AMPC amoxicillin, AZM azithromycin, CAM clarithromycin, CCL cefaclor, CDTR cefditoren, CFDN cefdinir, CFTM ce-
fteram, CPDX cefpodoxime, CTM cefotiam, CTRX ceftriaxone, CTX cefotaxime, FRPM faropenem, LVFX levoﬂoxacin, MEPM meropenem,
PAPM panipenem, PCG penicillin G, PIPC piperacillin, PISP penicillin-intermediate S. pneumoniae, PRSP penicillin-resistant S. pneumoniae,
PSSP penicillin-susceptible S. pneumoniae, RKM rokitamycin, TEL telithromycin, VCM vancomycin
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12.8 %, respectively, for PRSP, and 50.4, 50.9, 59.6, and
46.1 %, respectively, for PISP ? PRSP. In 2008, marked
decreases were seen in the proportions of PRSP and
PISP ? PRSP. Although there was a 1-year discrepancy in
the years in which the surveys were conducted, these trends
were similar to the present ﬁndings.
Clinical practice guidelines have been published one
after another, including the ‘‘Guidelines for the Manage-
ment of Respiratory Infectious Diseases in Children in
Japan’’ [9] in 2004, the ‘‘JRS Guidelines for the Manage-
ment of Community-Acquired Pneumonia in Adults’’ [10]
in 2005, and the ‘‘Treatment Guidelines for Acute Otitis
Media in Children’’ [11]. The Guidelines for the Manage-
ment of Respiratory Infectious Diseases in Children in
Japan were revised in 2007 and 2011, and the Treatment
Guidelines for Acute Otitis Media in Children were revised
in 2009 for the ediﬁcation of doctors and to encourage
proper use of antibacterial agents, including new drugs. In
Table 3 Resistance rate for each background factor in period 3 (2007)
Background factor S. pneumoniae PSSP PISP PRSP Resistant rate Statistical test
Number of strains Number of
strains (%)
Number of
strains (%)
Number of
strains (%)
(%)
Total 283 124 (43.8) 148 (52.3) 11 (3.9) 56.2
Sex
Male 148 66 (44.6) 78 (52.7) 4 (2.7) 55.4 Fisher
Female 124 53 (42.7) 64 (51.6) 7 (5.6) 57.3 P = 0.9537
Unknown 11 5 (45.5) 6 (54.5) 0 (0.0) 54.5
Age category
Infant 57 25 (43.9) 30 (52.6) 2 (3.5) 56.1 Fisher
Toddler and preschooler 203 84 (41.4) 110 (54.2) 9 (4.4) 58.6 P = 0.0663
School child 22 15 (68.2) 7 (31.8) 0 (0.0) 31.8
Unknown 1 0 (0.0) 1 (100.0) 0 (0.0) 100.0
Siblings
No 129 45 (34.9) 76 (58.9) 8 (6.2) 65.1 Fisher
Yes 153 79 (51.6) 71 (46.4) 3 (2.0) 48.4 P = 0.0056
Unknown 1 0 (0.0) 1 (100.0) 0 (0.0) 100.0
Daycare center attendee
No 111 51 (45.9) 58 (52.3) 2 (1.8) 54.1 Fisher
Yes 155 71 (45.8) 75 (48.4) 9 (5.8) 54.2 P = 0.0195
Unknown 17 2 (11.8) 15 (88.2) 0 (0.0) 88.2
Daycare center attendee (siblings)
No 25 12 (48.0) 12 (48.0) 1 (4.0) 52.0 v2
Yes 116 63 (54.3) 51 (44.0) 2 (1.7) 45.7 P = 0.5663
Unknown 142 49 (34.5) 85 (59.9) 8 (5.6) 65.5
Previous antibacterial agents
No 125 61 (48.8) 58 (46.4) 6 (4.8) 51.2 Fisher
Yes 156 62 (39.7) 89 (57.1) 5 (3.2) 60.3 P = 0.2488
Unknown 2 1 (50.0) 1 (50.0) 0 (0.0) 50.0
Penicillins
Yes 29 5 (17.2) 21 (72.4) 3 (10.3) 82.8
Unknown 254 119 (46.9) 127 (50.0) 8 (3.1) 53.1
Cephems
Yes 100 40 (40.0) 57 (57.0) 3 (3.0) 60.0
Unknown 183 84 (45.9) 91 (49.7) 8 (4.4) 54.1
Macrolides
Yes 53 28 (52.8) 23 (43.4) 2 (3.8) 47.2
Unknown 230 96 (41.7) 125 (54.3) 9 (3.9) 58.3
PISP penicillin-intermediate S. pneumoniae, PRSP penicillin-resistant S. pneumoniae, PSSP penicillin-susceptible S. pneumoniae
514 J Infect Chemother (2013) 19:510–516
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addition, a S. pneumoniae vaccine for children put on the
market in 2010 has been gradually changing the treatment
of pediatric infections.
The results in this report may have been affected by the
above-described change in clinical practice, and more
detailed investigations are needed, for example, by drug use.
With regard to antibacterial sensitivity, drugs with an
MIC90 B 1 lg/ml for PRSP in period 3 and/or period 4
were CDTR, CFPN, CTRX, CTM, CFTM, FRPM, TBPM,
PAPM, MEPM, DRPM, VCM, TEL, and TFLX. After
excluding DRPM, TBPM, and TFLX, which were only
measured in period 4 and TEL, which was only measured
in period 3, only MEPM of the nine remaining drugs
showed a greater than fourfold increase in MIC 90 from
period 1 to period 4. S. pneumoniae is one of the major
etiological agents in pediatric infections, and based on the
sensitivity shown in this study, it is thought to be necessary
to select antibacterial agents based on drug disposition and
the administration route.
Ascertaining resistance status will lead not only to rec-
ommendations for appropriate antimicrobial treatment, but
also to controlling drug-resistant pathogens, and we plan to
continue conducting surveillance and providing informa-
tion in the future.
Table 4 Resistance rate for each background factor in period 4 (2010)
Background factor S. pneumoniae PSSP PISP PRSP Resistant rate Statistical test
Number of strains Number of strains (%) Number of
strains (%)
Number of
strains (%)
(%)
Total 459 106 (23.1) 229 (49.9) 124 (27.0) 76.9
Sex
Male 272 65 (23.9) 133 (48.9) 74 (27.2) 76.1 Fisher
Female 186 41 (22.0) 95 (51.1) 50 (26.9) 78.0 P = 0.7339
Unknown 1 0 (0.0) 1 (100.0) 0 (0.0) 100.0
Age category
Infant 98 21 (21.4) 51 (52.0) 26 (26.5) 78.6 v2
Toddler and preschooler 330 71 (21.5) 164 (49.7) 95 (28.8) 78.5 P = 0.0256
Schoolchild 31 14 (45.2) 14 (45.2) 3 (9.7) 54.8
Siblings
No 185 35 (18.9) 96 (51.9) 54 (29.2) 81.1 v2
Yes 274 71 (25.9) 133 (48.5) 70 (25.5) 74.1 P = 0.0812
Daycare center attendee
No 180 44 (24.4) 91 (50.6) 45 (25.0) 75.6 Fisher
Yes 251 55 (21.9) 126 (50.2) 70 (27.9) 78.1 P = 0.7893
Unknown 28 7 (25.0) 12 (42.9) 9 (32.1) 75.0
Daycare center attendee (siblings)
No 45 10 (22.2) 26 (57.8) 9 (20.0) 77.8 Fisher
Yes 206 56 (27.2) 98 (47.6) 52 (25.2) 72.8 P = 0.1586
Unknown 208 40 (19.2) 105 (50.5) 63 (30.3) 80.8
Previous antibacterial agents
No 204 51 (25.0) 103 (50.5) 50 (24.5) 75.0 v2
Yes 255 55 (21.6) 126 (49.4) 74 (29.0) 78.4 P = 0.3861
Penicillins
Yes 60 13 (21.7) 32 (53.3) 15 (25.0) 78.3
Unknown 399 93 (23.3) 197 (49.4) 109 (27.3) 76.7
Cephems
Yes 127 29 (22.8) 67 (52.8) 31 (24.4) 77.2
Unknown 332 77 (23.2) 162 (48.8) 93 (28.0) 76.8
Macrolides
Yes 107 21 (19.6) 50 (46.7) 36 (33.6) 80.4
Unknown 352 85 (24.1) 179 (50.9) 88 (25.0) 75.9
PISP penicillin-intermediate S. pneumoniae, PRSP penicillin-resistant S. pneumoniae, PSSP penicillin-susceptible S. pneumoniae
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